Lineage Cell Therapeutics (LCTX) Intangibles (2010 - 2026)

Lineage Cell Therapeutics' Intangibles history runs 17 years deep, the most recent figure standing at $31.7 million for Q1 2026.

• In Q1 2026, Intangibles changed N/A year-over-year to $31.7 million; the TTM figure through Mar 2026 stood at $31.7 million (changed N/A YoY), while the FY2025 annual figure was $31.7 million, down 31.89% from the prior year.
• Intangibles for Q1 2026 stood at $31.7 million, roughly flat from $31.7 million in the prior quarter.
• The five-year high for Intangibles was $66.1 million in Q4 2022, with the low at $31.7 million in Q3 2025.
• The 5-year median for Intangibles is $46.6 million (2023), against an average of $51.4 million.
• The sharpest annual moves came in 2022 and 2025: Intangibles soared 213.34% in 2022, then tumbled 52.07% in 2025.
• Lineage Cell Therapeutics' Intangibles stood at $66.1 million in 2022, then declined by 29.6% to $46.6 million in 2023, then fell by 0.05% to $46.5 million in 2024, then slumped by 31.89% to $31.7 million in 2025, then changed by 0.0% to $31.7 million in 2026.
• Business Quant data shows LCTX's Intangibles at $31.7 million in Q1 2026, $31.7 million in Q4 2025, and $31.7 million in Q3 2025.